Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Subscribe To Our Newsletter & Stay Updated